KARYOPHARM THERAPEUTICS ($KPTI) posted quarterly earnings results for Q4 2025 on Thursday, February 12th. The company reported earnings of -$2.23 per share, missing estimates of -$2.14 by $0.09. The company also reported revenue of $34,080,000, missing estimates of $36,173,280 by $-2,093,280.
You can see Quiver Quantitative's $KPTI stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
KARYOPHARM THERAPEUTICS Insider Trading Activity
KARYOPHARM THERAPEUTICS insiders have traded $KPTI stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.
Here’s a breakdown of recent trading of $KPTI stock by insiders over the last 6 months:
- LORI MACOMBER (EVP, CFO & Treasurer) sold 1,626 shares for an estimated $10,243
- RICHARD A. PAULSON (President and CEO) sold 1,257 shares for an estimated $8,082
- KRISTIN ABATE (Chief Accounting Officer) has made 0 purchases and 5 sales selling 712 shares for an estimated $4,439.
- RESHMA RANGWALA (EVP & Chief Medical Officer) sold 408 shares for an estimated $2,623
- STUART POULTON (EVP, Chief Development Officer) sold 401 shares for an estimated $2,578
- SOHANYA ROSHAN CHENG (EVP & Chief Commercial Officer) sold 325 shares for an estimated $2,089
- MICHAEL MANO (SVP, General Counsel&Secretary) sold 234 shares for an estimated $1,504
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
KARYOPHARM THERAPEUTICS Hedge Fund Activity
We have seen 19 institutional investors add shares of KARYOPHARM THERAPEUTICS stock to their portfolio, and 26 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- EVERSEPT PARTNERS, LP removed 257,154 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,681,787
- CITADEL ADVISORS LLC removed 206,781 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,352,347
- PALO ALTO INVESTORS LP removed 187,911 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,228,937
- BANK OF AMERICA CORP /DE/ removed 168,440 shares (-99.9%) from their portfolio in Q3 2025, for an estimated $1,101,597
- VANGUARD GROUP INC added 151,397 shares (+37.1%) to their portfolio in Q4 2025, for an estimated $1,114,281
- GEODE CAPITAL MANAGEMENT, LLC added 94,445 shares (+101.2%) to their portfolio in Q4 2025, for an estimated $695,115
- CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. added 57,212 shares (+inf%) to their portfolio in Q4 2025, for an estimated $421,080
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
KARYOPHARM THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $KPTI in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Cantor Fitzgerald issued a "Overweight" rating on 02/05/2026
- RBC Capital issued a "Outperform" rating on 11/04/2025
- HC Wainwright & Co. issued a "Buy" rating on 10/13/2025
- Baird issued a "Outperform" rating on 10/09/2025
To track analyst ratings and price targets for KARYOPHARM THERAPEUTICS, check out Quiver Quantitative's $KPTI forecast page.
KARYOPHARM THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $KPTI recently. We have seen 4 analysts offer price targets for $KPTI in the last 6 months, with a median target of $17.0.
Here are some recent targets:
- Brian Abrahams from RBC Capital set a target price of $19.0 on 11/04/2025
- Robert Burns from HC Wainwright & Co. set a target price of $15.0 on 10/13/2025
- Michael Ulz from Baird set a target price of $21.0 on 10/09/2025
- Edward Tenthoff from Piper Sandler set a target price of $12.0 on 10/09/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
